References
- Mahlich JC, Roediger-Schluga T. The determinants of pharmaceutical R&D expenditures: evidence from Japan. Rev Ind Organ. 2006;28:145–8.
- Ministry of Health, Labour and Welfare. Health and medical services. 2015. Available from: http://www.mhlw.go.jp/english/wp/wp-hw9/dl/02e.pdf.
- Shimura H, Masuda S, Kimura H. Analyzing the generic penetration trend in the Japanese dispensing market by therapeutic category. J Generic Med. 2012;9(2):55–62.
- Ogura S, Jakovljević M. Health financing constrained by population aging An opportunity to learn from Japanese experience. Ser J Exp Clin Res. 2014;15:157–159.
- Minister of Health, Labour, and Welfare. Creating a community where people are able to continue living in familiar settings with ease. 2016. Available from: http://www.mhlw.go.jp/english/policy/care-welfare/care-welfare-elderly/dl/health_and_welfare_bureau.pdf
- The Federation of Japanese Pharmaceutical Wholesalers Association. Amount of pharmaceutical sales by facility. 2014. Available from: http://www.jpwa.or.jp/jpwa/index-e.html
- Japan Pharmaceutical Association. Current State of the Bungyo. 2016. Available from http://www.nichiyaku.or.jp/kokumin.php?p=11219.
- Pharmaceutical and food safety Bureau, Separation of dispensing and prescribing drugs in Japan. 2014. Available from https://www.pmda.go.jp/files/000151977.pdf.
- Japan Fair Trade Commission. Report on Distribution of Pharmaceuticals. 2006. Available from http://www.jftc.go.jp/en/pressreleases/yearly_2006/sep/2006_sep_27.files/2006-Sep-27.pdf.
- Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan - Key conditions to successful evolution. Expert Rev Pharmacoeconomics Outcomes Res. 2014;14:181–194.
- Shimura H, Masuda S, Kimura H. Research and development productivity map: visualization of industry status. J Clin Pharm Ther. 2014;39:175–180.
- Fischer M, Albers S, Wagner N, et al. Dynamic marketing budget allocation across countries, products, and marketing activities. Marketing Sci. 2011;30(4):568–585.
- Sridhar S, Mantrala M, Albers S. Pharmaceutical detailing elasticities: a meta-analysis. In: Ding M, Eliashberg J, editors. Innovation and marketing in the pharmaceutical industry. New York: Springer; 2014. p. 531–556.
- The Federation of Japanese Pharmaceutical Wholesalers Association. JPWA Guidebook. 2011. Available from http://www.jpwa.or.jp/jpwa/index-e.html.
- Thomas LG. Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry. Strateg Manag J. 2004;25:865–886.
- Chressanthis G, Sfekas A, Khedkar P, et al. Determinants of pharmaceutical sales representative access limits to physicians. J Medical Marketing. 2014;14(4):220–243.
- Jackevicius CA, Chou MM, Ross JS, et al. Generic atorvastatin and health care cost. N Engl J Med. 2012;366(3):201–204.
- Janko K, Klemenc-Ketis Z, Petek-Ster M, et al. Family doctors’ views of pharmaceutical representatives: assessment scale development. Fam Pract. 2011;28(4):456–460.
- Alkhateeb FM, Khanfar NM, Clauson KA. Characteristics of physicians who frequently see pharmaceutical sales representatives. J Hosp Mark Public Relations. 2009;19:2–14.
- Minister of Health, Labour, and Welfare. Survey of Medical Institutions. 2014. Available from: http://www.mhlw.go.jp/toukei/list/79-1a.html
- Goodman LA, Kruskal WH. Measures of association for cross classifications III: approximate sampling theory. J Am Stat Assoc. 1963;58(302):310–364.
- Anderson BL, Silverman GK, Loewenstein GF, et al. Factors associated with physicians’ reliance on pharmaceutical sales representatives. Acad Med. 2009;84:994–1002.
- Armstrong D, Reyburn H, Jones R. A study of general practitioners’ reasons for changing their prescribing behavior. Bmj. 1996;312:949–952.
- Wright RF, Lundstrom WJ. Physicians’ perceptions on pharmaceutical sales representatives: a model for analysing the customer relationship. J Medical Marketing. 2004;4:29–38.